Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.06.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Robert Silasi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. Hauptthemen laut MEDLINE: Sepsis, Factor XI, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Themen: Sepsis
Abstract (Originalsprache)
BACKGROUND: Sepsis remains a major clinical challenge characterized by dysregulated immune response, coagulation abnormalities, and multiorgan failure, leading to high morbidity and mortality. OBJECTIVES: This study investigated the therapeutic potential of abelacimab, a monoclonal antibody targeting the plasma zymogen factor (F)XI, in a new baboon model of Staphylococcus aureus sepsis. METHODS: Healthy Papio anubis baboons were randomly assigned to control or abelacimab treatment groups. Both groups (n = 6, each) were intravenously infused with a median lethal (LD50) dose of live S aureus. The treatment group was administered abelacimab 30 minutes after the onset of bacterial infusion. Hematologic, coagulation, inflammatory, and organ function parameters were monitored for 7 days or until the animal exhibited signs of irreversible organ failure. Proteomic analysis was conducted to elucidate the underlying mechanisms by which abelacimab offered protection. RESULTS: All 6 abelacimab-treated baboons survived until the 7-day endpoint, while 3 out of 6 untreated controls succumbed to sepsis within 102 hours. Abelacimab significantly attenuated sepsis-induced coagulopathy without signs of bleeding, as evidenced by biochemical tests and pathology analysis. Treated animals exhibited decreased proinflammatory cytokines, diminished neutrophil activation, and preservation of endothelial integrity, collectively conferring robust protection against organ damage. Proteomic analysis revealed that abelacimab modulated pathways related to coagulation, inflammation, and tissue injury, contributing to improved survival outcomes. CONCLUSION: FXI inhibition by abelacimab offers significant protection by attenuating activation of coagulation, reducing inflammation, and preventing organ failure. Targeting FXI may be a promising therapeutic strategy for managing sepsis by addressing multiple facets of its complex pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
- Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Michale E. Keeling Center for Comparative Medicine and Research, University of Texas MD Anderson Cancer Center, Bastrop, Texas, USA.
- Anthos Therapeutics, Cambridge, Massachusetts, USA.
- Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA.
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
- NIH HHS
- Anthos Therapeutics
- National Institutes of Health
- National Science Foundation
- National Institute of General Medical Sciences
Zitieren
APA
Silasi, R., Keshari, R. S., Abe, T., Byrum, S. D., Regmi, G., Lupu, C., Georgescu, C., Simmons, J. H., Shamanaev, A., Moellmer, S. A., Puy, C., Shatzel, J. J., Province, D., Edmondson, R. D., Mackintosh, S. G., Avaritt, N. L., Bloomfield, D., Gailani, D., Tackett, A. J., …, & Lupu, F. (2025). Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.06.018
Vancouver
Silasi R, Keshari RS, Abe T, Byrum SD, Regmi G, Lupu C, et al. Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.06.018
BibTeX
@article{Silasi2025,
author = {Silasi, Robert and Keshari, Ravi S and Abe, Tomohiro and Byrum, Stephanie D and Regmi, Girija and Lupu, Cristina and Georgescu, Constantin and Simmons, Joe H and Shamanaev, Aleksandr and Moellmer, Samantha A and Puy, Cristina and Shatzel, Joseph J and Province, Dennis and Edmondson, Rick D and Mackintosh, Samuel G and Avaritt, Nathan L and Bloomfield, Dan and Gailani, David and Tackett, Alan J and McCarty, Owen J T and Lupu, Florea},
title = {Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.06.018}
}
EUVIMED